On Jul. 27, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases and Humanigen had executed a clinical trial agreement for lenzilumab, the company’s proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody drug candidate. Lenzilumab was to be evaluated in the NIAID-sponsored Big Effect Trial in hospitalized patients with COVID-19.